AgonOx’s OX40 Platform Being Utilized In MedImmune’s Phase 1 OX40 Agonist Study

PORTLAND, Ore.--(BUSINESS WIRE)--AgonOx, a biotechnology company focused on immunotherapy development, today announced that its OX40 platform is being utilized in MedImmune’s Phase I trial of its humanized OX40 agonist, MEDI6383. MedImmune is the global biologics research and development arm of AstraZeneca. MedImmune licensed the OX40 agonist platform in 2011 from AgonOx as the result of a partnership between the Providence Cancer Center and AgonOx, a spin-off company from the Providence Cancer Center.

Help employers find you! Check out all the jobs and post your resume.

Back to news